IGF-1 LR3 carries significant safety concerns including hypoglycemia and potential effects on tumor growth. It is not approved for human use and lacks the safety data of approved medications. Use carries substantial risks.

How is IGF-1 LR3 different from regular IGF-1?

IGF-1 LR3 has modifications that reduce binding protein affinity, resulting in much higher free peptide levels and a half-life of 20-30 hours versus ~15 minutes for native IGF-1. This makes it significantly more potent.

Can IGF-1 LR3 cause hypoglycemia?

Yes. IGF-1 has insulin-like effects and can lower blood glucose. Hypoglycemia is a well-documented risk with IGF-1 administration and can be severe or even life-threatening if not managed.

Is IGF-1 LR3 banned in sports?

Yes. IGF-1 LR3 and all IGF-1 variants are prohibited by WADA both in-competition and out-of-competition as anabolic agents (S2).

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Hormonal & Endocrine•Updated 2026-02-01•5 min read

What Is IGF-1 LR3? Benefits, Research & Safety

A modified, highly potent analogue of insulin-like growth factor 1 with extended half-life and reduced binding protein affinity.

Share:X Post LinkedIn

Also known as:

Long R3 IGF-1

Long Arginine 3-IGF-1

LR3-IGF-1

DAnimal/cell evidence onlyUK: Unlicensed (UK)WADA: Prohibited in sport

UK summary: Not a licensed UK medicine. A potent IGF-1 analogue with extended half-life and reduced binding-protein affinity. Prohibited at all times under WADA S2 (IGF-1 and analogues). Theoretical cancer-promotion concerns are not fully resolved.

Quick Facts

Overview

IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor 1) is a synthetic, modified analogue of naturally occurring IGF-1. It consists of 83 amino acids compared to the 70 of native IGF-1, with specific modifications that dramatically alter its pharmacological properties. The "Long" refers to a 13-amino acid extension at the N-terminus, while "R3" indicates an arginine substitution at position 3. These modifications reduce binding to IGF binding proteins (IGFBPs), resulting in significantly increased bioavailability and a much longer half-life compared to native IGF-1. IGF-1 is one of the primary mediators of growth hormone's anabolic effects, playing crucial roles in growth, development, and tissue repair throughout life. By reducing IGFBP binding, IGF-1 LR3 has much greater potency than native IGF-1 on a per-molecule basis. This peptide has attracted significant interest in research settings for studying IGF-1 physiology and in the bodybuilding community for its potent anabolic effects. However, it carries significant safety concerns related to its potency and potential for serious adverse effects. IGF-1 LR3 is not approved for human use and is classified as a research compound. It is prohibited in sport by WADA.

Evidence standards summary

IGF-1 LR3 — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. A potent IGF-1 analogue with extended half-life and reduced binding-protein affinity. Prohibited at all times under WADA S2 (IGF-1 and analogues). Theoretical cancer-promotion concerns are not fully resolved.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

CLimited human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed for any indication. Research compound only. Prohibited in sport.
EU: Not approved for human use in any EU member state.
Notes: IGF-1 LR3 is not approved anywhere for human therapeutic use. Native recombinant IGF-1 (mecasermin/Increlex) is approved for specific growth disorders but is different from IGF-1 LR3. WADA prohibits IGF-1 LR3 in sport.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Adds muscle mass faster than any natural training stimulus.
Safe to inject site-specifically for localised muscle growth.
Reverses sarcopenia in healthy adults.
Undetectable in standard drug tests.

07Common internet claims

Marketed as the strongest legal anabolic peptide.
Recommended in bodybuilding stacks alongside HGH, testosterone, and insulin.
Promoted for use in-between bulk and cut cycles for muscle preservation.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Builds muscle without affecting blood sugar”	D	No	High	IGF-1 analogues can affect glucose metabolism; muscle-building claims in healthy adults are not supported by human trial data.
“Safe long-term”	E	No	High	Long-term IGF-1 elevation has theoretical cancer-promotion concerns that are not fully resolved.
“Allowed in untested sports”	E	No	High	Prohibited at all times under WADA S2; strict-liability applies regardless of testing schedule.

09Safety uncertainty score

Very high

Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.

10Known adverse signals

Hypoglycaemia (IGF-1 binds insulin receptor at high doses).
Carpal tunnel symptoms, joint pain, organ growth at sustained exposure.
Theoretical promotion of pre-existing cancers — IGF-1 is mitogenic.
Cardiac and renal hypertrophy reported with chronic IGF-1 elevation.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Prohibited in sportWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Not licensed for any indication. Research compound only. Prohibited in sport.

Read the full UK legal guide → Peptides and athletes (UK)

14EU legal position

Not approved for human use in any EU member state.

15What this page cannot tell you

Whether a UK-purchased vial contains IGF-1 LR3 at the labelled concentration.
How it interacts with insulin, testosterone, or growth hormone in a typical stack.
What the cancer risk is from sustained supraphysiological IGF-1 in young healthy adults.
Whether it triggers WADA detection — assume yes, prohibition is strict-liability.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

No published Phase 3 trials for any indication in healthy adults.
Long-term oncologic surveillance data does not exist.
Combination-stack safety entirely uncharacterised.
Detection-window data from WADA is intentionally restricted.

19Safer alternatives / established care pathways

Structured progressive-overload resistance training with adequate protein intake.
GP review for testosterone or growth hormone deficiency if clinically suspected.
Licensed mecasermin (Increlex) only when there is genuine severe primary IGF-1 deficiency under a specialist.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is IGF-1 LR3 a licensed UK medicine?
What are the theoretical cancer-related risks of chronic IGF-1 elevation?
If I'm tested in sport, what is my WADA exposure?
What licensed alternatives exist for the underlying goal?

Discovery & History

IGF-1 (Insulin-like Growth Factor 1) was first characterised in the 1970s and recognised as a key mediator of growth hormone's biological effects. Understanding of its physiology led to therapeutic development of recombinant human IGF-1 (mecasermin) for certain growth disorders. The development of IGF-1 LR3 arose from efforts to create more potent and longer-lasting analogues for research purposes. Scientists discovered that native IGF-1's biological activity is largely regulated by IGF binding proteins (IGFBPs), which sequester the hormone and limit its free, active concentration. By engineering specific modifications—the N-terminal extension and the arginine substitution—researchers created a variant with dramatically reduced IGFBP binding. This resulted in much higher free IGF-1 activity and a significantly extended half-life. IGF-1 LR3 became a valuable research tool for studying IGF-1 physiology independent of binding protein regulation. It allowed researchers to examine the effects of sustained, high IGF-1 receptor activation. The peptide never progressed to clinical development due to safety concerns related to its potency. However, it became available through research chemical suppliers and gained popularity in bodybuilding communities, leading to concerns about unregulated use.

Mechanism of Action

IGF-1 LR3 exerts its effects through potent activation of the IGF-1 receptor (IGF-1R), with reduced regulation by binding proteins: **Reduced IGFBP Binding** The structural modifications dramatically reduce affinity for IGF binding proteins: - Native IGF-1 is >90% bound to IGFBPs in circulation - IGF-1 LR3 has much lower IGFBP affinity - Results in much higher free, biologically active peptide - Contributes to both increased potency and longer half-life **IGF-1 Receptor Activation** IGF-1 LR3 maintains full ability to activate the IGF-1 receptor: - Triggers intracellular signaling cascades (PI3K/Akt, MAPK pathways) - Promotes protein synthesis and inhibits protein breakdown - Stimulates cell proliferation and differentiation - Inhibits apoptosis (cell death) **Anabolic Effects** The downstream effects include: - Increased muscle protein synthesis - Enhanced nitrogen retention - Stimulation of satellite cell activation (muscle stem cells) - Potential effects on fat metabolism - Support of tissue repair and regeneration **Glucose Metabolism** IGF-1 has insulin-like effects on glucose metabolism: - Can lower blood glucose - Potential for hypoglycaemia, especially at higher doses - Cross-reactivity with insulin receptor at high concentrations

Researched Benefits

Based on preclinical and clinical research findings:

1
Potent stimulation of muscle protein synthesis
2
Enhanced nitrogen retention and anabolic environment
3
Extended half-life compared to native IGF-1
4
Research tool for studying IGF-1 physiology
5
Potential tissue repair and regeneration effects
6
Possible hyperplasia (new muscle cell formation) in addition to hypertrophy

Claim vs Evidence

How popular claims about IGF-1 LR3 stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Builds muscle without affecting blood sugar”	D	No	High	IGF-1 analogues can affect glucose metabolism; muscle-building claims in healthy adults are not supported by human trial data.
“Safe long-term”	E	No	High	Long-term IGF-1 elevation has theoretical cancer-promotion concerns that are not fully resolved.
“Allowed in untested sports”	E	No	High	Prohibited at all times under WADA S2; strict-liability applies regardless of testing schedule.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	20-100 mcg per day (from research literature; wide variation)
Frequency	Once daily or divided doses
Duration	4-6 weeks cycles commonly cited in research literature
Notes	⚠️ IGF-1 LR3 is not approved for human use and carries significant safety risks. These protocols are extrapolated from research settings and anecdotal reports. Hypoglycemia is a serious risk. Medical supervision is essential.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection
Intramuscular injection (some research protocols)

Half-Life	Stability
20-30 hours (compared to ~15 minutes for native IGF-1)	Requires careful handling; lyophilised powder stored at -20°C; reconstituted solution refrigerated

Safety Profile & Known Risks

Commonly Reported Side Effects

Hypoglycaemia (low blood sugar) - potentially severe
Joint pain and swelling
Jaw pain or growth
Headaches
Water retention
Injection site reactions

Rare Risks & Concerns

Severe hypoglycaemia (medical emergency)
Acceleration of tumour growth (potent mitogen)
Organ growth (heart, intestines)
Acromegaly-like effects with chronic use
Cardiomyopathy with prolonged use
Unknown long-term effects

Contraindications

Active or history of cancer (potent growth factor)
Diabetes or hypoglycaemic tendency
Pregnancy and breastfeeding
Children and adolescents (except under specialist care)
Cardiovascular disease
Any condition where cell proliferation is concerning

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed for any indication. Research compound only. Prohibited in sport.

🇪🇺 European Union

Not approved for human use in any EU member state.

IGF-1 LR3 is not approved anywhere for human therapeutic use. Native recombinant IGF-1 (mecasermin/Increlex) is approved for specific growth disorders but is different from IGF-1 LR3. WADA prohibits IGF-1 LR3 in sport.

Clinical Studies Summary

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.

LR3 promotes favorable effects on Aβ plaque remodeling in cortex of male 5XFAD mice but fails to preserve aspects of behavior or memory. While these data do not support LR3 as a monotherapy per se, they do warrant further investigation into its potential for combinatorial formulations aimed at targeting the complexity of AD.

J Alzheimers Dis. 2025View on PubMed

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.

• Purified IGF-1 and LR3 IGF-1 show bioactivity comparable to the standard IGF-1. • High heterologous expression of IGF-1 and LR3 IGF-1 is achieved by fermentation in a bioreactor.

Appl Microbiol Biotechnol. 2023View on PubMed

Looking for IGF-1 LR3?

Source research-grade IGF-1 LR3 from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about IGF-1 LR3